ABOUT
About Hera Biotech
We’re Not Closing Gaps—We’re Rebuilding What Never Should’ve Been Missing
Because early answers, diagnostic confidence, access, and clinical fit shouldn’t be revolutionary—they should be routine.
The System Didn’t Just Delay Diagnosis—It Was Designed That Way
Endometriosis. Reproductive cancers. These aren’t edge cases. They’re the diagnostic failures millions of women live through every day.
The tools to detect them? Still optimized for acute infections, male physiology, and insurance-driven bottlenecks, not for conditions that evolve with hormones, shift with cycles, or worsen without escalation.
Hera’s platform replaces that legacy with diagnostic infrastructure built for biology that cycles and decisions that can’t wait—finally enabling accurate diagnosis for two common diseases.
What We’re Building
A modular diagnostic platform engineered to confront the systemic gaps in women’s health—starting with two of the most mismanaged conditions in medicine.
A non-invasive test for endometriosis detection and staging, powered by gene expression analysis, proprietary biomarkers, and ML-trained signal classifiers.
A point-of-care diagnostic device delivering cervical cancer diagnosis in minutes, using AI-enhanced optical and electrical spectroscopy.
The Team Translating Biology into Architecture
This isn’t a founding team—it’s a precision-assembled coalition of strategists, scientists, engineers, and operators who’ve brought category-defining tools to the life science market, again and again.
Their disciplines didn’t just align.
Together, they’re building the backbone diagnostics always needed in women’s health—rooted in biology, calibrated to care, and finally capable of seeing what legacy tools missed.
0
Years of Experience
EXECUTIVE LEADERSHIP
2 exits. Former VC & Director of Clinical Operations, Santalias Pharmaceuticals
Somer Baburek, MBAPresident, CEO, & Board Member
Multi-patent holder. Exited founder. Former R&D Director, Scailyte
Cinzia Donato, PhDCOO & CSO
Former VC. Life science consultant.
Matt Baburek, MBACFO & Controller
9 exits, 20+ years in diagnostics & VC. Inventor of Trichomonas rapid test.
Paul Castella, PhD, MBACBO & Executive Chairman
PRODUCT & TECHNOLOGY
Jesus Seañez, PhD, BSHead of Product & Technology
Yeimi Arreola, MSc, BScProduct Design Engineer
Abel Chavez, MSc, BScSoftware Engineer
Marco Ramirez, MSc, BScProduct Manufacturing Engineer
DATA SCIENCE
Neal Smith, MSc, BScLead Data Scientist
REGULATORY & COMMERCIAL
Teo Tijerina, MBA, BSHead of Commercial Partnerships & Development, Board Member
Kelly Mottet, MSc, BScHead of Quality Management & Regulatory Affairs
Toni Villa, BACommunications & Marketing Expert
SCIENTIFIC ADVISORS
Dr. Ricardo Lúa Alvarado, MD, OB-GYN (Mex), MSc, Dip HSMClinical Advisor
Shayna Mancuso, D.O., FACOG Clinical Advisor
BOARD OF DIRECTORS
Paul Castella, PhD, MBACBO & Executive Chairman
Somer Baburek, MBAPresident, CEO, & Board Member
Ayse McCracken, MBA Board Observer
Dr Wendy M Smith, DSc, MHABoard Member
Teo Tijerina, MBA, BSHead of Commercial Partnerships & Development, Board Member
Neill “Gobie” Walsdorf, JrBoard Member
Built to Correct What the System Missed.
0
Exits
0
Years Experience
They’ve engineered diagnostics from concept to clearance.
Led clinical trials that reshaped care.
Exited nine companies that pushed life sciences forward.
But Hera isn’t just the sum of past wins. It’s the convergence of biology, data science, clinical execution, and regulated delivery—aligned around one goal: to make timely, tissue-level diagnosis the new standard in women’s health.
The team brings a shared intolerance for “business as usual”—and the precision to build what never should’ve been missing.
Named for a Protector.
Built to End the Wait.
Before Hera, patients waited—through pain, silence, and ambiguity.
We didn’t just name the gap.
We built what was missing: diagnostic infrastructure engineered for diagnostic complexity, clinical urgency, and tissue-level precision.
Like the goddess we’re named for, Hera exists to protect women—only now, wielding scientific precision and diagnostic equity instead of myth.
Strategic Partners
Hera is partnering with clinical leaders to advance, adapt, and deliver a new diagnostic model—one designed to meet women’s health conditions at their source, not after they escalate.
Academic, Clinical, and Scientific Collaborator
Academic partner co-developing endometriosis biomarker discovery
Investors Backing Our Mission
These aren’t just biotech investors—they’re conviction-led partners that understand the regulatory, scientific, and systemic shifts required to build the diagnostic correction women’s health demands.
Backing the Next Standard in Women’s Health
Accelerating AI-Enabled Care Delivery
Driving Precision Innovation in Clinical Settings
Advancing Regulated Innovation from Bench to Bedside
Fueling Healthcare Solutions That Redefine Access
Backing Female Founders Redefining Women’s Health
Backing Early-Stage Visionaries Across Global Markets
The Diagnostic Standard Women Deserved—Now Delivered
No more surgical confirmation. No more late-stage default. No more “come back in six months.”
Hera delivers biologically grounded, clinically actionable diagnostics—on time, from tissue, and on terms that match how women actually experience disease.
Because answers should come early, fit her biology, and finally earn her trust.